RxDoctor Payments Data

Aliu Sanni, MD

General Surgery · Loganville, GANPI 1629226758

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (41.7%), food and beverage and education — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.1% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $4,545 and has fallen 87.6% since, to $564 in 2025.

$6,102in general payments, 2019–2025

Across 91 payments — averaging $67.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Medical Device Business Services, Inc.$1K
  • Novo Nordisk$596
  • Johnson & Johnson$216
  • Baxter Healthcare$98
  • Lilly USA, LLC$48
  • plus $325 from 13 others
$1,226,644in research payments, 2019–2025

Across 971 payments — averaging $1263.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$668K
  • Eli Lilly$336K
  • Pfizer$92K
  • GSK$73K
  • Bausch Health US, LLC$39K
  • AstraZeneca$19K

What the payments were for

  • Travel & lodging$2,54242%
  • Food & beverage$2,31938%
  • Education$1,24120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,102 in reported general payments places this provider in the 85th percentile of 29 general surgery providers in Georgia.

See all general surgery providers in Georgia

Medicare billing

Part B allowed, 2024
$10,752
Medicare patients
20
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide30$38,721
ShingrixVaricella-Zoster Ge/As01b/Pf127$26,387
ArexvyRsvpref3 Antigen/As01e/Pf68$19,992
AbrysvoRsv Vacc, Pref A And Pref B/Pf34$10,202
MresviaRsv Vaccine, Pref, Mrna/Pf25$7,382
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20$147
Ondansetron Hcl27$137
Omeprazole23$73
Ibuprofen18$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$48$38,72130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 29 general surgery providers in Georgia.

Other general surgery in Loganville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →